OCUL vs. TAK
Compare and contrast key facts about Ocular Therapeutix, Inc. (OCUL) and Takeda Pharmaceutical Company Limited (TAK).
Performance
OCUL vs. TAK - Performance Comparison
Loading graphics...
OCUL vs. TAK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
OCUL Ocular Therapeutix, Inc. | -30.23% | 42.15% | 91.48% | 58.72% | -59.68% | -66.33% | 424.05% | -0.75% | -10.56% | -46.83% |
TAK Takeda Pharmaceutical Company Limited | 18.79% | 23.18% | -3.12% | -4.87% | 20.08% | -23.45% | -5.18% | 22.48% | -38.84% | 41.29% |
Fundamentals
OCUL:
$1.89B
TAK:
$59.36B
OCUL:
-$1.38
TAK:
$36.10
OCUL:
31.49
TAK:
0.01
OCUL:
2.89
TAK:
0.01
OCUL:
$51.95M
TAK:
$4.49T
OCUL:
$45.25M
TAK:
$2.79T
OCUL:
-$258.96M
TAK:
$1.39T
Returns By Period
In the year-to-date period, OCUL achieves a -30.23% return, which is significantly lower than TAK's 18.79% return. Over the past 10 years, OCUL has underperformed TAK with an annualized return of -1.51%, while TAK has yielded a comparatively higher 1.65% annualized return.
OCUL
- 1D
- 14.46%
- 1M
- -5.26%
- YTD
- -30.23%
- 6M
- -27.54%
- 1Y
- 15.55%
- 3Y*
- 17.14%
- 5Y*
- -13.42%
- 10Y*
- -1.51%
TAK
- 1D
- 1.37%
- 1M
- -1.23%
- YTD
- 18.79%
- 6M
- 26.50%
- 1Y
- 27.35%
- 3Y*
- 7.79%
- 5Y*
- 3.44%
- 10Y*
- 1.65%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
OCUL vs. TAK — Risk / Return Rank
OCUL
TAK
OCUL vs. TAK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Ocular Therapeutix, Inc. (OCUL) and Takeda Pharmaceutical Company Limited (TAK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| OCUL | TAK | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.21 | 1.30 | -1.09 |
Sortino ratioReturn per unit of downside risk | 0.91 | 1.76 | -0.85 |
Omega ratioGain probability vs. loss probability | 1.11 | 1.23 | -0.12 |
Calmar ratioReturn relative to maximum drawdown | 0.20 | 2.24 | -2.03 |
Martin ratioReturn relative to average drawdown | 0.52 | 5.82 | -5.30 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| OCUL | TAK | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.21 | 1.30 | -1.09 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.17 | 0.18 | -0.35 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.02 | 0.07 | -0.09 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.05 | 0.12 | -0.16 |
Correlation
The correlation between OCUL and TAK is 0.16, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
OCUL vs. TAK - Dividend Comparison
OCUL has not paid dividends to shareholders, while TAK's dividend yield for the trailing twelve months is around 1.74%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
OCUL Ocular Therapeutix, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
TAK Takeda Pharmaceutical Company Limited | 1.74% | 4.24% | 4.67% | 4.41% | 4.23% | 2.98% | 2.30% | 4.20% | 4.77% | 2.81% | 3.99% | 2.92% |
Drawdowns
OCUL vs. TAK - Drawdown Comparison
The maximum OCUL drawdown since its inception was -95.19%, which is greater than TAK's maximum drawdown of -54.25%. Use the drawdown chart below to compare losses from any high point for OCUL and TAK.
Loading graphics...
Drawdown Indicators
| OCUL | TAK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.19% | -54.25% | -40.94% |
Max Drawdown (1Y)Largest decline over 1 year | -57.29% | -12.83% | -44.46% |
Max Drawdown (5Y)Largest decline over 5 years | -89.14% | -30.09% | -59.05% |
Max Drawdown (10Y)Largest decline over 10 years | -90.94% | -54.25% | -36.69% |
Current DrawdownCurrent decline from peak | -80.43% | -18.51% | -61.92% |
Average DrawdownAverage peak-to-trough decline | -76.58% | -23.22% | -53.36% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 22.71% | 4.94% | +17.77% |
Volatility
OCUL vs. TAK - Volatility Comparison
Ocular Therapeutix, Inc. (OCUL) has a higher volatility of 19.52% compared to Takeda Pharmaceutical Company Limited (TAK) at 6.63%. This indicates that OCUL's price experiences larger fluctuations and is considered to be riskier than TAK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| OCUL | TAK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.52% | 6.63% | +12.89% |
Volatility (6M)Calculated over the trailing 6-month period | 58.02% | 13.96% | +44.06% |
Volatility (1Y)Calculated over the trailing 1-year period | 75.47% | 21.17% | +54.30% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 78.73% | 19.34% | +59.39% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 80.20% | 23.02% | +57.18% |
Financials
OCUL vs. TAK - Financials Comparison
This section allows you to compare key financial metrics between Ocular Therapeutix, Inc. and Takeda Pharmaceutical Company Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities